Cytomegalovirus (CMV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cytomegalovirus
(CMV) is a ubiquitous virus that infects the majority of humans of all ages.
CMV is a member of the herpes virus family which includes the herpes simplex
viruses and the viruses that cause chickenpox and mononucleosis. Human
cytomegalovirus (HCMV) is a species of the Cytomegalovirus genus of viruses, of
the viral family Herpes viridae or herpes viruses, and is the most common of
all cytomegaloviruses. The primary infection manifests as an asymptomatic or
self-limited febrile illness in immuno-competent individuals, after which CMV
establishes life-long latency in various cells which serve as reservoirs for
reactivation and as carriers of infection to susceptible individuals. The
method of spread of this infection varies. Direct contact with body fluids from
an infected person exposes an individual to CMV. Most healthy children and
adults do not experience any symptoms after infection with CMV. However, CMV
may cause serious disease in people with a weakened immune system (such as
those with HIV/AIDS or those taking medications that suppress immunity). CMV
can cause retinitis (blurred vision and blindness), painful swallowing
(dysphagia), pneumonia, diarrhea (colitis), and weakness or numbness in the
legs.
·
The incidence of CMV infection is found out to
be 35% in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients.
However, within the transplant patients, 34% to 40% of patients developed at
least one CMV episode at 12 months and 88% of patients develop at least one CMV
episode within 6 months.
Thelansis’s
“Cytomegalovirus (CMV) Infection Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Cytomegalovirus
(CMV) Infection treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cytomegalovirus (CMV)
Infection across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cytomegalovirus
(CMV) Infection Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Cytomegalovirus
(CMV) Infection, Cytomegalovirus (CMV) Infection market
outlook, Cytomegalovirus (CMV) Infection competitive
landscape, Cytomegalovirus (CMV) Infection market
forecast, Thelansis, Primary market research, KOL insights, Competitive
Intelligence (CI)
Comments
Post a Comment